View in EDS HTML Full Text PDF Full Text

CRL4AMBRA1 targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling.

Saved in:
Bibliographic Details
Title: CRL4AMBRA1 targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling.
Authors: Chen SH; Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA, USA.; Biophysics Graduate Program, University of California, San Francisco, San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Gladstone Institutes, San Francisco, CA, USA., Jang GM; Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Gladstone Institutes, San Francisco, CA, USA., Hüttenhain R; Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Gladstone Institutes, San Francisco, CA, USA., Gordon DE; Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Gladstone Institutes, San Francisco, CA, USA., Du D; Department of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA., Newton BW; Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Gladstone Institutes, San Francisco, CA, USA., Johnson JR; Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Gladstone Institutes, San Francisco, CA, USA., Hiatt J; Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA, USA.; Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA.; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.; Diabetes Center, University of California, San Francisco, San Francisco, CA, USA., Hultquist JF; Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Gladstone Institutes, San Francisco, CA, USA., Johnson TL; Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Gladstone Institutes, San Francisco, CA, USA., Liu YL; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA., Burton LA; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA., Ye J; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Reichermeier KM; California Institute of Technology, Pasadena, CA, USA., Stroud RM; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA., Marson A; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.; Diabetes Center, University of California, San Francisco, San Francisco, CA, USA.; Division of Infectious Diseases and Rheumatology, University of California, Berkeley, Berkeley, CA, USA.; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.; Chan Zuckerberg Biohub, San Francisco, CA, USA., Debnath J; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Gross JD; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA., Krogan NJ; Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA, USA nevan.krogan@ucsf.edu.; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.; Gladstone Institutes, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Source: The EMBO journal [EMBO J] 2018 Sep 14; Vol. 37 (18). Date of Electronic Publication: 2018 Aug 30.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8208664 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2075 (Electronic) Linking ISSN: 02614189 NLM ISO Abbreviation: EMBO J Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1460-2075
DOI:10.15252/embj.201797508